Chris Coffey

Started as a Buc. Vol for Life. Tar Heel brED. Hawkeye faculty. Clinical trialist. Otherwise, just a big kid.

[The Science of Parkinson's @ScienceofPD]

An invited editorial explores how the @MichaelJFoxOrg's PPMI programme is enabling the first interventional platform trial ("Path to Prevention" or P2P) to test therapies in individuals with Early-Stage Neuronal Alpha-Synuclein Disease
https://t.co/JYi16oNMiB

[The Science of Parkinson's @ScienceofPD]

An invited editorial describes lessons learned from prior enrollment & current strategies for enrolling participants to the @MichaelJFoxOrg PPMI programme prior to the diagnosis of #Parkinsons or dementia with Lewy Bodies
https://t.co/LfjiVmkMKk

[Chris Coffey @proffcoff]

“Can you give me a quick sample size calculation for my grant due in three days?”

Me:

[David Eickholt @DavidEickholt]

This will be frequently used:

[NCAA March Madness @MarchMadnessWBB]

SOLD-OUT CROWD IN IOWA CITY‼️

If you aren't watching women's sports, you're missing out!

#MarchMadness x @IowaWBB

[Chris Coffey @proffcoff]

@christen_rexing But he has to get it from an actual restaurant where the food looks a bit different than what he has in his videos

[Cure Parkinson's @CureParkinsonsT]

Stakeholders involved in Parkinson’s platform trials met for the second annual International PD-Platform Meeting. They launched the Global Alliance for Parkinson’s Platforms (GAPP), bringing together international leaders of Parkinson’s platform trials: https://t.co/KY1zqz2hJK

[Chris Coffey @proffcoff]

We are nearing the time of year when I have to pay special attention to whether I am watching a show/movie on Hallmark or ID so that I know when a girl meets a guy whether they are going to fall in love or he is going to murder her.

[Chris Coffey @proffcoff]

@ehlJAMA For the question about identifying the assigned group, isn’t the hypothesis that the answer should be correct about 50% of the time by chance if they are just guessing? So the smaller percentage is more significant because it is farther from 50% (chance).

[Michael Okun @MichaelOkun]

Can 'light therapy' help people w/ Parkinson’s sleep better? The ENLITE-PD randomized study put this idea to the test. Aleksandar Videnovic and colleagues did a great job on this multi-center effort. Spoiler alert: bright white light therapy was not effective.
Key Points:
- Bright white light therapy was safe, well tolerated and had good adherence across groups.
- Twice-daily light therapy showed some improvements in sleep and fatigue, however it did not meet criteria to advance to a phase 3 trial.
- Once weekly bright light was non-inferior to dim red light and may serve as a better control condition for future studies.
My take: I think it is critically important to put non-pharmacological therapies to the test, and I congratulate the authors for conducting this study. Right now, it looks light the ‘juice may not be worth the squeeze’ for the current versions of light therapy for Parkinson’s. Here are 5 points that resonated w/ me about this article: 1- Sleep issues frequently affect people living w/ Parkinson’s and remain a major unmet need. 2- Light therapy is safe and may help improve fatigue and aspects of sleep, however the benefits were modest in this trial. 3- Not all light therapies are the same and more research is needed to determine frequency, timing and type of light that work best. 4- This study highlights the importance of rigorous trials to sort out real benefits from placebo and also from the effects of daily rhythm. 5- Future light therapy studies will need longer durations, diverse populations and objective measures to truly understand if there is a potential we are missing.
https://t.co/1lR8pYujF9 @FixelInstitute @ParkinsonDotOrg @movedisorder @SfNtweets

[Chris Coffey @proffcoff]

Great movie. I usually recommend it to students in my clinical trials course. There is a “twist” that is very relevant to some of the course discussions.

[Chris Coffey @proffcoff]

@MassGenBrigham @PaganoniMDPhD Congrats, Sabrina. Extremely well deserved

[Chris Coffey @proffcoff]

@FadeAwayMedia LA & Punk - Yeah!!

[Emily Roberts @emilyk_roberts]

If you'll be at #JSM2025 next week, come check out some of our @Iowa_Biostat current students and faculty present their research!

[@ExTINGUISHTrial @extinguishtrial]

The ExTINGUISH Trial Methods Paper is available, Open Access!

👉There are no approved (or rigorously studied) treatments for NMDAR Encephalitis.
👉 Enrollment is ongoing for newly diagnosed NMDAR Encephalitis patients, via NIH/NINDS & the NeuroNEXT Clinical Trial Network

[Chris Coffey @proffcoff]

Tonight is #MLBAllStarGame2025

It always reminds me of one of the most “statistician” things I did as a kid.

I would keep score each year and using different color pencils for each player - with the color matching the player's team colors (red for Reds, blue for Dodgers, etc.)

[Chris Coffey @proffcoff]

@JayinSTL Title win would have been tainted a bit for Fletcher here. Rhodes likely a great choice as a transitional champion. And can drop the belt to Fletcher.

[NINDS @NIH_NINDS]

Join NINDS for "Challenges in Pediatric Neuroscience Research: Bench to Bedside" with Dr. Sunny Juul & Dr. Elizabeth Berry-Kravis.

July 30, 2025 | 12-1 PM ET

Register now: https://t.co/eIvQSuetwC

[Chris Coffey @proffcoff]

@ScienceofPD @EJS_ACT_PD @CureParkinsonsT Very exciting!

[Chris Coffey @proffcoff]

@HonoraryDawg It’s also the little details. Watch Seth help with the ladder from the mat.

[Stacey Clardy MD PhD @StaceyLClardy]

Just published 👉

A NEWLY updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: Analysis, equipoise, and the urgent need for evidence over anecdote 🧠🔥

Why is this paper so important ?

1/